Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis

Toyama, Tadashi; L. Neuen, Brendon; Jun, Min; Ohkuma, Toshiaki; Neal, Bruce; Jardine, Meg; J.L. Heerspink, Hiddo; Geot Wong, Muh; Ninomiya, Toshiharu; Wada, Takashi; Perkovic, Vlado

doi:10.1111/dom.13648

Public

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis

Published in Diabetes Obesity and Metabolism • Jan 29, 2019

Authors:

Tadashi Toyama

Brendon L. Neuen

Min Jun

Abstract

Aim The use of sodium glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily because glycaemic efficacy is dependent on kidney function. We performed a systematic review and meta‐analysis to assess the...

Subject

Medicine

Renal function

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!